The OTCQX Market is designed for established, investor-focused
“Trading on the OTCQX is a great affirmation of Mountain Valley MD’s ability to meet the highest financial standards of the OTCQX Market and being current in our governance and financial disclosures. We continue to pursue advancements that will provide a large
Investors can find Real-Time quotes and market information for MVMDF on www.otcmarkets.com. The Company continues to trade on the Canadian Securities Exchange under the ticker symbol “MVMD” and the
MVMD Listing Strategy
On
As part of its evaluation process, the Company has completed an initial review of its listing options with its Board of Directors, including how an up-listing strategy coincides with evaluation of plans to become listed on a senior exchange in
“It is important that we advance our up-listing strategy in concert with anticipated advances in our science and commercialization efforts to ensure institutional and retail investors have access to our shares," continued
ABOUT OTC MARKET GROUP INC.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 11,000
To learn more about the OTC Markets Group Inc., visit www.otcmarkets.com.
OTC Link ATS and OTC Link ECN are
ABOUT
- patented Quicksome™ oral drug formulation and delivery technologies,
- patented Quicksol™ solubility formulation technology, and
Consistent with its vision towards “Helping People Live Their Best Life”, MVMD applies its Quicksome™ and Quicksol™ technologies to its work for advanced delivery of vaccines and pharmaceutical drugs as well as the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more.
MVMD’s patented Quicksome™ desiccation technology utilizes advanced liposomes and other stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats that are consumed orally. The result is a new generation of product formulations that could be capable of delivering vaccines, drugs and nutraceuticals into the body faster, with greater impact, efficiency and accuracy.
MVMD’s patented Quicksol™ technology covers all highly solubilized macrocyclic lactones that could be effectively applied in multiple viral applications that could positively impact human and animal health globally. When Quicksol™ technology is applied to the ivermectin drug in its Ivectosol™ format, it is the only form in the world that only uses excipients that are currently approved by the
For more Company information and contact details, visit www.mountainvalleymd.com.
SOURCE:
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "will", "intend", "should", and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information.
The Company's actual results could differ materially from those anticipated in this forward-looking information as a result of regulatory decisions, competitive factors in the industries in which the Company operates, prevailing economic conditions, and other factors, many of which are beyond the control of the Company.
The Company is making forward-looking statements, including but not limited to with respect to: the up-listing of its common shares on the OTCQB and the implications thereof; matters related to the further up-listing of its securities on exchanges in both
The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.
For further information:Dennis Hancock President and Chief Executive OfficerMountain Valley MD Holdings Inc. Investor Relations @ 647-725-9755 Email: dennis@mountainvalleymd.com www.mountainvalleymd.com
Source:
2021 GlobeNewswire, Inc., source